Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.
Stocks · News reference
8-K filing — Faeth Therapeutics, Inc. (FTH)
Filed: 2026-09-17 AccNo: 0001193125-26-394360 Size: 150 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.
TD Cowen Initiates Coverage On Faeth Therapeutics with Buy Rating